Document Type : Original Research
Authors
- Amir Hossein Jafarian
- Khatoone Mirshekar
- Sare Etemad
- Masoumeh Jafaripour
- Mansoore Darijani
- Maryam Sheikhi
- Hossein Ayatollahi
- Sepideh Shakeri
- Seyyede Fatemeh Shams
- Saeed Davari
Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Abstract
Background and Objective: BRAF mutations were studied in various populations for prostate carcinoma (PC); however, mutations in BRAF gene are unusual compared to KRAS. Oncogenic activating of BRAF mutations were studied lately in almost 0%-10% of prostate cancer cases.
Methods: In this retrospective study, we gathered 100 formalin-fixed paraffin-embedded samples of prostate adenocarcinoma. A hundred archived samples of adjacent benign prostatic hyperplasia were chosen as normal control. This study was done in pathology laboratory of Qaem Hospital during 2013-2015.
Results: Total number of 200 PC and normal cases was investigated for BRAF V600E mutation. The BRAF V600E mutation was found in only 4 patients but it was not detected in normal cases. There were no significant differences between patient and control groups for this mutation (P>0.99). The frequency of BRAF V600E mutation was not significant in different age groups (P>0.285); the most frequency was related to the age range of 71-80. No significant difference was observed between tumor grade and BRAF mutation (P=0.21).
Conclusion: According to our findings, BRAF gene mutations did not play essential role in PC. Therefore, anti-BRAF (V600E) could not be considered as a proper target for therapy.
Keywords
Main Subjects
)